30 closest matches · ranked by relevance
Ranitidine Adverse Reaction · Pharmacokinetics · Food-drug Interaction
Primary: Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Ranitidine and Placebo) — 0.6; 10.5; 11.9; 23.4 nanograms — p=0.54
Coronary Artery Disease · Drug Interaction Potentiation
Primary: Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, After One Week of Randomized…
Gastroesophageal Reflux Disease (GERD)
Primary: Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26 — 32.9; 84.9 Percentage of Participants
Dyspepsia
Primary: Visual Analogue Scale Score — 39.6; 42.3; 27.6; 28.3 Visual Analogue Scale
Gastroesophageal Reflux Disease (GERD)
Primary: Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26 — 31.7; 88.4 Percentage of Participants
Gastric Ulcer
Primary: The Percentage of Subjects Whose Gastric Ulcer(s) (GUs) Was (Were) Healed at Week 4 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients…
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib — 21600; 19100; 21000…
Oncology Patients Receiving Chemotherapy
Primary: Number of Hypersensitivity Reactions to Treatment With an Anti-CD20 Antibody or Paclitaxel — 2; 3 Participants
Non-tuberculous Mycobacterial Diseases · Tuberculosis · Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections
Primary: Number of Patients With Adverse Drug Reactions in This Surveillance — 16; 7 Participants
Tuberculosis · Non-tuberculous Mycobacterial Diseases (Including MAC Disease)
Primary: Number of Participants With Treatment-Related Adverse Events — 387; 113 Participants
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Gastrointestinal Diseases
Primary: Maximal Measured Plasma Concentration (Cmax) of Rabeprazole — 393.50; 415.83 Nanograms per milliliter
Peptic Ulcer
Primary: Number of Participants With Healed Peptic Ulcer — 106; 101 participants
HIV
Primary: Maximum Observed Plasma Concentration (Cmax) and Trough Observed Plasma Concentration (Ctrough) for Atazanavir and Ritonavir — 3512; 4131; 3322; 496 ng/mL
Panic Disorder
Primary: Number of Participants of Treatment Related Adverse Events (TRAEs) — 110 participants
Breast Neoplasms
Primary: Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane — 126; 324; 372; 68 participants
Pulmonary Arterial Hypertension · Right Heart Failure
Primary: Change in Six-minute Walk Distance — -17.0; 4.7 meters
Multiple Sclerosis · Infusion Reaction
Primary: Proportion of Participants With Infusion-related Reaction (IRR) on Day 0 — 5; 6 participnats
Angina · Pulmonary Arterial Hypertension
Primary: Improve Angina Symptoms — 1.75 units on a scale — p=0.0013
Acute Urticaria
Primary: Change of Patient Rated Pruritus Score — -1.61; -1.50 score on a scale
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) — 94.37; 43.84; 106.35; 51.65 ng/mL
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
Gastrointestinal Diseases
Primary: Mean Maximal Measured Plasma Concentration (Cmax) After a Single Dose — 543.78; 530.34 Nanogram per mL (ng/mL)
Seizures
Primary: Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine — 15.2; 13.1; 1.15; 2.13 nmol per mg creatinine
Gastroesophageal Reflux
Primary: Determination of Median Time to Sustained Partial Response as Defined by Reduction in Likert Severity Scale Used to Assess Pain Associated With Heartburn in the Patient…
Overactive Bladder
Primary: Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs). — 984 participants
Acute Urticaria
Primary: Extent of Urticaria/Erythema Score (Physician Assessment) — 1.91; 1.74; 1.53; 1.12 units on a scale
Persistent Atrial Fibrillation
Primary: Time From Randomization to First Documented AF Recurrence. — 51.0; NA; 117.0; 58.0 Days
Nephrolithiasis
Primary: USSQ Urinary Symptom Score — 28; 29; 16; 17 score on a scale
Gastrointestinal Stromal Tumors
Primary: Number of Participants With Treatment-Related Adverse Events — 450 Participants